category,datetime,headline,id,image,related,source,summary,url
company,1769014020,Becton Dickinson & Co. stock underperforms Wednesday when compared to competitors despite daily gains,138213526,,BDX,MarketWatch,Becton Dickinson & Co. stock underperforms Wednesday when compared to competitors despite daily gains,https://finnhub.io/api/news?id=e6132429aacb7851dd68ee150af0d8ebf365d8d5d4f2b1dc1d9405b513618404
company,1769013780,BD Gets FDA 510(k) Approval for EnCor EnCompass Breast Biopsy System,138198293,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,BDX,Yahoo,"BDX wins FDA 510(k) clearance for the EnCor EnCompass breast biopsy system, set for an early 2026 launch to boost flexibility and patient care.",https://finnhub.io/api/news?id=bc239500a396d0c504bcfe9c67d3ca3e52fde1923a2112da5857b46a8329c9ce
company,1768996200,BD and Ypsomed Expand Partnership to Address Rapidly Growing Biologics Market,138194483,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,BDX,Yahoo,"BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Ypsomed, a leading developer of injection systems, are strengthening their collaboration with the development of a 5.5 mL version of the BD Neopak™ XtraFlow™ Glass Prefillable Syringe. This innovation is designed to be fully compatible with Ypsomed's YpsoMate® 5.5 autoinjector platform, expanding options for pharmaceutical companies and patients who require large‑volume subcutaneous self‑injections.",https://finnhub.io/api/news?id=f3a932a70979d8f3ccb8f0643d678852458dffaea073cf3db61d4202b3e525e0
